Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Immuno-Oncology and Technology is Scopus-indexed (Q1, CiteScore 8.6), DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 2590-0188Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 69 / 428 | 83rd | Q1 |
| Immunology and Allergy | 48 / 234 | 79th | Q1 |
Not listed in: Web of Science, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q1, CiteScore 8.6.
Immuno-Oncology and Technology is Q1 in Oncology (rank 69 of 428) and Q1 in Immunology and Allergy (rank 48 of 234), by CiteScore 2025.
Immuno-Oncology and Technology is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 8.6, quartile Q1, 83rd percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.883, quartile Q1, with an H-index of 17.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$3,340 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Immuno-Oncology and Technology is published by Elsevier Inc. Its ISSN is 2590-0188.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Yes — it is an open-access journal, listed in DOAJ.
Immuno-Oncology and Technology has an h-index of 22 and a 2-year mean of 0.45 citations per paper (OpenAlex). Its Scopus CiteScore is 8.6, quartile Q1. On 2-year citations it ranks #341 of 424 Scopus journals in Oncology.
Immuno-Oncology and Technology published 407 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 81 research articles (2025–2026), authors are most often from United Kingdom (10.7%), United States (10.3%) and Denmark (9.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.